Media stories about Summit Therapeutics (NASDAQ:SMMT) have trended somewhat positive on Tuesday, Accern Sentiment Analysis reports. The research group identifies positive and negative media coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Summit Therapeutics earned a media sentiment score of 0.24 on Accern’s scale. Accern also gave media coverage about the company an impact score of 46.8010853188396 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.

Summit Therapeutics (NASDAQ SMMT) traded up $0.10 during mid-day trading on Tuesday, hitting $10.36. The stock had a trading volume of 11,900 shares, compared to its average volume of 21,893. Summit Therapeutics has a 12 month low of $7.95 and a 12 month high of $16.86.

Several research firms have recently weighed in on SMMT. Zacks Investment Research downgraded Summit Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, September 6th. ValuEngine downgraded Summit Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, October 5th. Canaccord Genuity reiterated a “buy” rating and set a $28.00 price target on shares of Summit Therapeutics in a research note on Monday, September 11th. Oppenheimer reiterated a “buy” rating and set a $24.00 price target on shares of Summit Therapeutics in a research note on Monday, October 16th. Finally, HC Wainwright reiterated a “buy” rating and set a $16.00 price target on shares of Summit Therapeutics in a research note on Thursday, December 7th. One analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and an average price target of $20.25.

ILLEGAL ACTIVITY NOTICE: “Somewhat Positive News Coverage Somewhat Unlikely to Affect Summit Therapeutics (SMMT) Stock Price” was first published by Watch List News and is owned by of Watch List News. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright & trademark legislation. The original version of this news story can be viewed at https://www.watchlistnews.com/somewhat-positive-news-coverage-somewhat-unlikely-to-affect-summit-therapeutics-smmt-stock-price/1773228.html.

About Summit Therapeutics

Summit Therapeutics plc is a biopharmaceutical company, which is engaged in drug development. The Company is focused on the discovery, development and commercialization of medicines for indications for which there are no existing or only inadequate therapies. It is conducting clinical programs focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI).

Insider Buying and Selling by Quarter for Summit Therapeutics (NASDAQ:SMMT)

Receive News & Ratings for Summit Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Summit Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.